Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Фаза 1
Завершено
NCT03239145
| Заболевание | Advanced Solid Tumor |
|---|
| Фаза | Фаза 1 |
|---|
| Спонсор | Dana-Farber Cancer Institute |
|---|
| Статус | Завершено |
|---|
| Участники | 62 участн. |
|---|
| Вмешательство | Pembrolizumab, Trebananib |
|---|
| Дата начала | 1.05.2018 |
|---|
| Дата завершения | 13.12.2024 |
|---|
| Публикация результатов | 12.03.2026 |
|---|
Кратко
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386
Number of Participants Experienced Dose Limit Toxicities (DLT)
3 weeks · Participants
| [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 0 Participants |
|---|
| [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 0 Participants |
|---|
Maximum Tolerated Dose (MTD) of Trebananib
3 weeks · mg/kg
| [Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib | 30 mg/kg |
|---|
Grade 3 or Higher Toxicity Rate in Expansion Cohort
The median follow up time was 3.3 months (range: 0.6 to 25.3 months). · percentage of participants
| [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 59.5 percentage of participants |
|---|
| Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 63.6 percentage of participants |
|---|
| Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 75.0 percentage of participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.